These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 34642300)

  • 1. Stat1 confers sensitivity to radiation in cervical cancer cells by controlling Parp1 levels: a new perspective for Parp1 inhibition.
    Raspaglio G; Buttarelli M; Filippetti F; Battaglia A; Buzzonetti A; Scambia G; Gallo D
    Cell Death Dis; 2021 Oct; 12(10):933. PubMed ID: 34642300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MAPK4 deletion enhances radiation effects and triggers synergistic lethality with simultaneous PARP1 inhibition in cervical cancer.
    Tian S; Lou L; Tian M; Lu G; Tian J; Chen X
    J Exp Clin Cancer Res; 2020 Jul; 39(1):143. PubMed ID: 32711558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A combined ANXA2-NDRG1-STAT1 gene signature predicts response to chemoradiotherapy in cervical cancer.
    Buttarelli M; Babini G; Raspaglio G; Filippetti F; Battaglia A; Ciucci A; Ferrandina G; Petrillo M; Marino C; Mancuso M; Saran A; Villani ME; Desiderio A; D'Ambrosio C; Scaloni A; Scambia G; Gallo D
    J Exp Clin Cancer Res; 2019 Jun; 38(1):279. PubMed ID: 31242951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models.
    Frederick BA; Gupta R; Atilano-Roque A; Su TT; Raben D
    Radiat Res; 2020 Nov; 194(5):519-531. PubMed ID: 32936912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib.
    Bianchi A; Lopez S; Altwerger G; Bellone S; Bonazzoli E; Zammataro L; Manzano A; Manara P; Perrone E; Zeybek B; Han C; Menderes G; Ratner E; Silasi DA; Huang GS; Azodi M; Newberg JY; Pavlick DC; Elvin J; Frampton GM; Schwartz PE; Santin AD
    Gynecol Oncol; 2019 Oct; 155(1):144-150. PubMed ID: 31434613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property.
    Prasad CB; Prasad SB; Yadav SS; Pandey LK; Singh S; Pradhan S; Narayan G
    Sci Rep; 2017 Oct; 7(1):12876. PubMed ID: 28993682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiosensitization with an inhibitor of poly(ADP-ribose) glycohydrolase: A comparison with the PARP1/2/3 inhibitor olaparib.
    Gravells P; Neale J; Grant E; Nathubhai A; Smith KM; James DI; Bryant HE
    DNA Repair (Amst); 2018 Jan; 61():25-36. PubMed ID: 29179156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MAPK4 silencing together with a PARP1 inhibitor as a combination therapy in triple‑negative breast cancer cells.
    Zeng X; Jiang S; Ruan S; Guo Z; Guo J; Liu M; Ye C; Dong J
    Mol Med Rep; 2021 Aug; 24(2):. PubMed ID: 34080025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo.
    van Erp AEM; van Houdt L; Hillebrandt-Roeffen MHS; van Bree NFHN; Flucke UE; Mentzel T; Shipley J; Desar IME; Fleuren EDG; Versleijen-Jonkers YMH; van der Graaf WTA
    J Cancer Res Clin Oncol; 2020 Jul; 146(7):1659-1670. PubMed ID: 32279088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer.
    Karnak D; Engelke CG; Parsels LA; Kausar T; Wei D; Robertson JR; Marsh KB; Davis MA; Zhao L; Maybaum J; Lawrence TS; Morgan MA
    Clin Cancer Res; 2014 Oct; 20(19):5085-96. PubMed ID: 25117293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PARP inhibitor Olaparib increases the sensitization to radiotherapy in FaDu cells.
    Liu C; Gross N; Li Y; Li G; Wang Z; Zhong S; Li Y; Hu G
    J Cell Mol Med; 2020 Feb; 24(4):2444-2450. PubMed ID: 31957270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HMGA2 as a functional antagonist of PARP1 inhibitors in tumor cells.
    Hombach-Klonisch S; Kalantari F; Medapati MR; Natarajan S; Krishnan SN; Kumar-Kanojia A; Thanasupawat T; Begum F; Xu FY; Hatch GM; Los M; Klonisch T
    Mol Oncol; 2019 Feb; 13(2):153-170. PubMed ID: 30289618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
    Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition.
    Han S; Brenner JC; Sabolch A; Jackson W; Speers C; Wilder-Romans K; Knudsen KE; Lawrence TS; Chinnaiyan AM; Feng FY
    Neoplasia; 2013 Oct; 15(10):1207-17. PubMed ID: 24204199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor suppressive effect of PARP1 and FOXO3A in gastric cancers and its clinical implications.
    Park SH; Jang KY; Kim MJ; Yoon S; Jo Y; Kwon SM; Kim KM; Kwon KS; Kim CY; Woo HG
    Oncotarget; 2015 Dec; 6(42):44819-31. PubMed ID: 26540566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poly ADP-ribose polymerase-1 as a potential therapeutic target in Merkel cell carcinoma.
    Ferrarotto R; Cardnell R; Su S; Diao L; Eterovic AK; Prieto V; Morrisson WH; Wang J; Kies MS; Glisson BS; Byers LA; Bell D
    Head Neck; 2018 Aug; 40(8):1676-1684. PubMed ID: 29570891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of APE1 potentiates breast cancer cells to olaparib by inhibiting PARP-1 expression.
    Ma X; Dang C; Min W; Diao Y; Hui W; Wang X; Dai Z; Wang X; Kang H
    Breast Cancer Res Treat; 2019 Jul; 176(1):109-117. PubMed ID: 30989461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
    Du Y; Yamaguchi H; Wei Y; Hsu JL; Wang HL; Hsu YH; Lin WC; Yu WH; Leonard PG; Lee GR; Chen MK; Nakai K; Hsu MC; Chen CT; Sun Y; Wu Y; Chang WC; Huang WC; Liu CL; Chang YC; Chen CH; Park M; Jones P; Hortobagyi GN; Hung MC
    Nat Med; 2016 Feb; 22(2):194-201. PubMed ID: 26779812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MORC2 regulates DNA damage response through a PARP1-dependent pathway.
    Zhang L; Li DQ
    Nucleic Acids Res; 2019 Sep; 47(16):8502-8520. PubMed ID: 31616951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poly(ADP-ribosyl)ation of BRD7 by PARP1 confers resistance to DNA-damaging chemotherapeutic agents.
    Hu K; Wu W; Li Y; Lin L; Chen D; Yan H; Xiao X; Chen H; Chen Z; Zhang Y; Xu S; Guo Y; Koeffler HP; Song E; Yin D
    EMBO Rep; 2019 May; 20(5):. PubMed ID: 30940648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.